Announced Fri, 24 Jul · 14:11 IST
Dr Lal PathLabs Q1 FY27 results: Revenue Rs 798 Cr, up 19.1%, PAT Rs 170 Cr
Compliance View source PDF
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+7.7%1-day move
₹1690.10
prior close
₹1703.50
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.7+0.7+0.6+0.4+7.7—————————
Up moveDown movePending
AI summary
Dr Lal PathLabs Q1 FY27 consolidated revenue rose 19.1% YoY to Rs 798 Cr. EBITDA up 28.7% at Rs 247 Cr (margin 31.0%). PAT grew 27.2% to Rs 170 Cr (margin 21.4%). EPS at Rs 10.1 vs Rs 7.9. Board declared 50% interim dividend (Rs 5 per share). Cash and equivalents at Rs 1,693 Cr. Company acquired 80% stake in Ghana's Sunshine Healthcare (up to GHS 45.6 million) and 30% in Neuome Technologies (up to Rs 3.5 Cr).
Likely market impact
Strong quarter with revenue, EBITDA, and PAT all growing above 25% YoY. Interim dividend plus two acquisitions signal growth and shareholder returns.